Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma
Open Access
- 13 July 2020
- Vol. 12 (7), 1895
- https://doi.org/10.3390/cancers12071895
Abstract
Due to chemoresistance and a high propensity to form lung metastasis, survival rates in pediatric osteosarcoma (OS) are poor. With the aim to improve anticancer activity in pediatric OS, a multidrug nanomedicine was designed using the alkyl-lysophospholipid edelfosine (EF) co-assembled with squalenoyl–gemcitabine (SQ–Gem) to form nanoassemblies (NAs) of 50 nm. SQ–Gem/EF NAs modified the total Gem pool exposure in the blood stream in comparison with SQ–Gem NAs, which correlated with a better tolerability and a lower toxicity profile after multiple intravenous administrations in mice. For in vivo preclinical assessment in an orthotopic OS tumor model, P1.15 OS cells were intratibially injected in athymic nude mice. SQ–Gem/EF NAs considerably decreased the primary tumor growth kinetics and reduced the number of lung metastases. Our findings support the candidature of this anticancer nanomedicine as a potential pediatric OS therapy.This publication has 44 references indexed in Scilit:
- Genome-wide association study identifies two susceptibility loci for osteosarcomaNature Genetics, 2013
- Common Musculoskeletal Tumors of Childhood and AdolescenceMayo Clinic Proceedings, 2012
- Squalene Based Nanocomposites: A New Platform for the Design of Multifunctional Pharmaceutical TheragnosticsACS Nano, 2011
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComputer Methods and Programs in Biomedicine, 2010
- Profiling of Chemonaive Osteosarcoma and Paired-Normal Cells Identifies EBF2 as a Mediator of Osteoprotegerin Inhibition to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced ApoptosisClinical Cancer Research, 2009
- Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in MiceDrug Metabolism and Disposition, 2008
- Preclinical Toxicology (Subacute and Acute) and Efficacy of a New Squalenoyl Gemcitabine Anticancer NanomedicineThe Journal of pharmacology and experimental therapeutics, 2008
- A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia typesJournal of Controlled Release, 2007
- Squalenoyl Nanomedicines as Potential TherapeuticsNano Letters, 2006
- Osteoblasts are target cells for transformation in c-fos transgenic miceThe Journal of cell biology, 1993